On Wednesday, Mednow Inc (OTCMKTS:MDNWF) came up with a major new announcement that investors could do well to look into. The company announced that it had been chosen by the Reformulary Group Inc as the preferred digital pharmacy. It was a major new development for Mednow considering the fact that it would allow the company to offer the experience of its 300,000 strong members.
Trading Data
On Wednesday, MDNWF stock ended flat at $0.1967 with more than 1K shares, compared to its average volume of 2.85K shares. The stock moved within a range of $0.1967 – 0.1967 after opening trade at $0.1967.
Reformulary Group Inc. and Mednow Inc. Partner to Advance the Mission of Making Medications More Transparent, More Accessible, and More Affordable for All Canadians
The number of members on its platform continues to grow. In this context, it should be noted that Reformulary Group had been responsible for building and then managing its proprietary drug list, The Reformulary and went on to become the most recognized independent formulary in Canada. Its Drugfinder search tool had also won awards
By way of this particular partnership, Mednow would be able to offer the managed formularies from Reformulary to its fast growing client network. The partnership would also help the users of the Mednow to get assistance from the expert advice functions by Reformulary so as to discover just the right medicine that is suitable for any issue. Additionally, the partnership also has the provision for creating a new drug for Canadians that would be affordable and transparent.
